Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, Skype calls, conferences, and what-not has, of course, returned. No surprise, though, because the world keeps spinning no matter how much we try to hit the brake pedal. So to cope, please join us for a delightful cup of stimulation. Our choice today is peppermint mocha, for those keeping track. Meanwhile, here are some tidbits. Hope you have a smashing day and do keep in touch. …

The Food and Drug Administration declined to approve a drug developed by Sanofi (SNY) and Lexicon Pharmaceuticals (LXRX)  intended for use with insulin in patients with Type 1 diabetes, Reuters writes. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division and faces increasing pressure from politicians and patient groups over the rising cost of its insulin products.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy